Markets
INO

Inovio Pharmaceuticals (INO) Falls: Stock Plunges 13.4% - Tale of the Tape

A pen next to a calculator.
Credit: Shutterstock photo

Inovio Pharmaceuticals, Inc. ( INO ) saw a big move last session, as the company's shares fell by over 13% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for INO as the stock is now up around 7.6% in the past one-month time frame.

This slump shouldn't be too much of a surprise to investors, as Inovio Pharmaceuticals has seen 2 negative revisions in the past few weeks and its current year consensus loss estimates have widened over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.

INO currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Some better-ranked stocks in the pharmaceutical industry include ANI Pharmaceuticals, Inc. ( ANIP ), Gilead Sciences Inc. ( GILD ) and Illumina Inc. ( ILMN ). All these stocks hold a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

INOVIO PHARMAC (INO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

INO

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More